METHOD OF TREATMENT OF A NEUROPATHIC PAIN
20180008570 · 2018-01-11
Assignee
Inventors
- Meng-Jen Lee (Nantou City, TW)
- Hsin-Sheng Tsay (Taichung City, TW)
- Huang-Chi Wang (Kaohsiung City, TW)
Cpc classification
A61K9/0019
HUMAN NECESSITIES
A61K9/19
HUMAN NECESSITIES
A61K31/341
HUMAN NECESSITIES
A61K47/20
HUMAN NECESSITIES
International classification
Abstract
A method of treatment of a neuropathic pain by administering an andrographolide to the subject is provided. The andrographolide treatment may relief the symptom of neuropathic pain by reducing the astrocytic activity.
Claims
1. A method of treatment of a neuropathic pain in a subject, comprising: administering an andrographolide to the subject to relief the symptom of the neuropathic pain by reducing the activity of astrocytes.
2. The method of claim 1, wherein the reducing of the astrocytic activity includes reducing the cellular level of glial fibrillary acidic protein (GFAP).
3. The method of claim 1, wherein the neuropathic pain is a central nervous system pain.
4. The method of claim 1, wherein the causes of the neuropathic pain include spinal cord trauma, cerebrovascular disease, multiple sclerosis, a tumor, diabetic peripheral neuropathy, herpes zoster, a HIV-AIDS, a chronic injury, an acute injury or an autoimmune disorder.
5. The method of claim 1, wherein the andrographolide is administered to the subject in a therapeutically effective amount.
6. The method of claim 1, wherein the andrographolide is administered orally, intraperitoneally, intravenously, intramuscularly, or subcutaneously to the subject.
7. The method of claim 1, wherein a medicament containing the andrographolide includes an acceptable carrier, a diluent, or an excipient.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] The present invention provides a method of treatment of a neuropathic pain by administering an andrographolide to the subject. It is herein confirmed that andrographolide compounds can reduce the activity of astrocytes to relief the neuropathic pain induced by the central nervous system.
[0026] The causes of neuropathic pain induced by the central nervous system include a spinal cord injury (such as an interruption or dysfunction of pain transmission in the central nervous system), a cerebrovascular disease, multiple sclerosis, or a tumor. The causes of neuropathic pain induced by the peripheral nervous system include diabetic peripheral neuropathy, herpes zoster infection, HIV-AIDS, a chronic injury (such as from repetitive motion disorder), an acute injury (such as a surgical wound) or an autoimmune disorder. Although neuropathic pain can be caused by peripheral or central nervous, persistent peripheral nervous inflammation may also induce central nervous inflammation, and this may lead to an aggravation of allodynia, the symptom of sensing pain from normally non-painful stimuli.
[0027] A medicament containing andrographolide may include an acceptable carrier, diluent or excipient, and may be administered to a patient as oral medication, an intraperitoneal injection, intravenous injection, intramuscular injection or subcutaneous injection. The dose or frequency may be adjusted according to the level of pain.
[0028] The following embodiment is provided to illustrate the effects that an andrographolide compound has in alleviating neuropathic pain.
[0029] Preparation and Processing of the Medicament
[0030] Lyophilized andrographolide powder is dissolved in DMSO and subsequently diluted to 2.86 mM (1 mg/mL) in 90% normal saline and 10% DMSO for storage. The mixture is injected into the peritoneum (body cavity) of each animal (intraperitoneal injection) based on 5 mg/kg animal weight, for example, a 30 g mouse is injected with 150 μL of saline containing 0.15 mg of andrographolide. NSAID drugs (Diclofenac sodium salt) may be purchased from Sigma (D6899), and diluted to 2.86 mM (0.91 mg/mL) in 90% saline and 10% DMSO for storage. The NSAID drugs is administered via intraperitoneal injection based on 5 mg/ml animal weight, for example, a 30 g mouse is injected with 165 μL of saline containing 0.15 mg of NSAID drugs. The number of molecules administered is less in andrographolide treated mouse than in NSAID drugs treated rats. These drugs are administered daily after surgery.
[0031] The sciatic nerve transaction (SNT) is used for simulating a neuropathic pain model
[0032] An operation for inducing the sciatic nerve transaction of BALB/c mice is processing as follows. After isoflurane anesthesia is applied to male BALB/c mice, which have about 8 weeks of age and have a weight of approximately 30 g, the skin of the right thigh is slit to expose the muscle. Then a blunt instrument is used to spread open the biceps femoris to expose the sciatic nerve and its three nerve branches, which are the sural nerve, common peroneal nerve and tibial nerve. Then a sterilized no. 4-0 chromium wire is used to tie the sciatic nerve, and approximately 2-4 mm of the ends of the common peroneal nerve and the tibial nerve are cut at a position near the tying position. Care is taken to avoid touching and stretching the sural nerve. The muscle and skin are closed in two separate layers. For sham surgery, the sciatic nerve is exposed as described above but no contact is made with the nerve. In this embodiment, the nerve is tied to a level such that there is slight sheathing of the nerve in order to avoid affecting the blood circulation in the area. The mice's behavior is observed after several days of rest.
[0033] Manner of Administration
[0034] The experiment is separated into the following groups that receive different treatments. In the normal group, no surgery is carried out and no andrographolide or NSAID drugs are administered to mice. In the pain group (OP-saline), saline is given to mice daily after surgery. In the control group (Op-NSAIDs), Diclofenac sodium salt is administered to mice daily after surgery. In the experimental group (Op-AP), an andrographolide compound is administered to mice daily after surgery. The means of administration is by intraperitoneal injection. The concentration of drugs for both the control group and the experimental group is 5 mg/kg animal weight, and the average animal weight is 30 g. For the model that uses an in vivo sciatic nerve transaction to simulate pathological pain, the mice behavior is tested on 3, 7, 14 days after surgery. The von Frey hair test is used to determinate the withdrawal threshold of the pathological pain.
[0035] Behavior Test by Von Frey Test
[0036] Mechanical allodynia threshold at the lateral plantar surface of the hindpaw is assessed before nerve injury (as basal pain threshold) and then testing began on day 3 after surgery and continued for 7 and 14 days after surgery. Mechanical sensitivity is determined by measuring the withdrawal thresholds and reaction ratio to von Frey hairs (Stoelting, Wood Dale, Ill.) using the up and- down method (Dixon 1980) as described by Chaplan (Chaplan, Bach et al. 1994). Animals were placed in a plastic cage with a wire net floor and were allowed to habituate 10-15 min before testing began. Animals were also habituated over a period of 2-3 consecutive days by recording a series of baseline measurements. The filaments were applied in ascending order, each 5 times at an interval of 2-3 s to the plantar surface of the hindpaw (Bourquin, Suveges et al. 2006) and the smallest filament eliciting a foot withdrawal response is considered the threshold stimulus. The withdrawal threshold (force of the von Frey hair to which an animal reacts in over 50% of the presentations) is recorded. For measuring withdrawal rate, 0.02 g hair and 0.07 g hair is selected. For each ten tests when using specific hair, the percentage of withdrawal behavior exhibited is noted. Of the 4 documented behavior types, reaction type I is regarded as no behavior, and type II-IV is regarded as reactive which describing below.
[0037] I. No feeling (The mouse′ hindpaw does not withdraw after more than 3 seconds).
[0038] II. Lifting leg (The mouse lifts its leg slowly back to the original position about 1-2 seconds after touching and flinching from the von Frey hair.
[0039] III. Moving away (The detecting leg is moved and its position is switched, and the withdrawal takes approximately 1 second).
[0040] IV. Moving away quickly (The mouse's whole body is moved and its position is switched).
[0041] Statistical Analysis Method
[0042] The data measured in this experiment is expressed in terms of the mean±standard deviation, and the data from each experimental group is compared using One-Way ANOVA to find any significant difference between them. When P<0.05 indicates that there is a statistically significant difference. For convenience in the statistical analysis, the number of animals of each group in this experiment is 6 to 8.
[0043] Collection of Tissue Samples
[0044] The following procedure is to ascertain the activity of astrocytic glial cells of the spinal cord. The mice are deeply anaesthetized with sevoflurane and perfused transcardially with saline followed by 0.1 M phosphate buffer solution containing 4% paraformaldehyde. The L4-L6 segment of spinal cord and left and right sciatic nerves are dissected out and post-fixed in a 4% parformaldehye solution at 4° C. overnight, and transferred to a series of solution of phosphate-buffered saline (PBS), graded ethanol/PBS, xylyne, graded xylyne/wax mixture, and finally embedded in wax. A rotary slicer for tissues is used to slice the sample to a transverse section with a thickness of 3 um, and warm water is used to spread and attach to the glass slice.
[0045] Immunohistochemical Staining
[0046] The wax sections are dewaxed in a series of xylene, graded xylene/ethanol mixture, or graded ethanol mixture, and finally incubation in PBS. The antigen is recovered by an antigen retrieval solution (R&D Systems, Inc., 614 McKinley Place Nebr., Minneapolis, Minn. 55413). The sections of spinal cord are incubated with 0.3% H.sub.2O.sub.2 for 30 minutes to remove endogenous hydrogen peroxide. An ABC kit (Vector laboratory) is used for chromogen development; or instead no primary antibodies are used, but rather only a secondary antibody is used to mark the background. The sections is left to incubate with primary antibody at 4° C. overnight, wherein the primary antibody is glial fibrillary acidic protein (GFAP) (1:1000, Dako, Carpinteria, Calif. USA), and the secondary antibody for fluorescent staining is IgG conjugated to Alexa 488, (1:800, Molecular Probes, Eugene, Oreg.).
[0047] Quantification by Immunoreactivity (IR)
[0048] The immunoreactivity in each group is analyzed, and the intensity of chromogen staining or fluorescence is determined by photo form 4-5 independent animals. The image of the photo is analyzed using the same settings for quantitative comparison. All measured pixels in a specific area are analyzed by the ImageJ software on 0 (black) to 255 (white) scales. The total number of pixels having a value less than 50 in the photo is calculated and used to estimate the value of immunoreactivity in the area of interest. The data is analyzed using One-Way ANOVA, and P<0.05 (*) indicates that the analysis have a statistically significant difference.
[0049] Result of the Analgesic Effect of Andrographolide Compound on Neuropathic Pain
[0050] Sciatic nerve transaction surgery is performed to the male BALB/c mice to induce neuropathic pain, and a von Frey hair is used to apply different pressures of stimulation to the animal at 3, 7 and 14 days after surgery, and used to determinate withdrawal thresholds and withdrawal rate of the animals.
[0051] Please refer to
[0052] Please refer to
[0053]
[0054] Please refer to
[0055] The result shows that the mice of the Op-AP group have a very significant low withdrawal rate at the 3, 7 and 14 days after surgery when compares with the Op-saline group. The OP-AP group has a very significant lower withdrawal rate at the 3, 7 and 14 days after surgery when compared with the Op-NSAID group, (the statistical p values are sequentially * or #: P<0.05, * * or ##: P<0.01, * * * or ###: P<0.005)), indicating a reduced pain behavior with use of andrographolide than the NSAID.
[0056] Please refer to
[0057] Please refer to
[0058] The results indicate the GFAP immunoreactivity of the astrocytes in the OP-AP group demonstrated a reduced trend toward to the OP-saline group. The results show that the andrographolide compound may contribute to the inhibition of the astrocytic activity in the spinal cord.
[0059] As disclosed in published literature, an upregulation expression of GFAP is generally regarded as an indicator of the astrocytic activation. The upregulation expression of GFAP and astrocytic hypertrophy are related to pains found in many pathological damages. As shown in
[0060] As described above, the results show that the andrographolide compound can provide relief from mechanical allodynia and allergic reactions, and the degree of relief is better than using the same dose of the NSAID drugs. The reduction in mechanical allodynia is consistent with the lower activity of astrocytes.
[0061] While the present invention has been described by means of a specific embodiment, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope and spirit of the invention set forth in the claims.